CSF1R and melanoma: In BRAF-therapy-resistant melanoma, combinatorial treatment with CSF-1R (PLX3397) and BRAF V600E (PLX4720) inhibitors at a low dose strongly increased the survival rate of murine xenograft models, as well as decreased the proliferation and invasiveness of cancer cell lines [13].